Keywords
overweight
respiratory function
leptin
How to Cite
Abstract
Chronic obstructive pulmonary disease (COPD) still remains a serious problem for the public health care system, since it commonly causes disability and mortality among the working population. Frequent combination of COPD with concomitant diseases is a key factor in predicting COPD consequences. Recently, the number of patients with a combination of COPD and overweight is on the increase, which is considered as a mutual aggravating factor and negatively affects the prognosis of the disease in such patients.
The objective of this study was to investigate the diagnostic value of leptin in progression of COPD (III degree of bronchial obstruction in patients with overweight) course by studying its level in blood serum.
Materials and methods: There were examined 112 patients with chronic obstructive pulmonary disease (COPD GOLD III) in different phases of pathological process. The pulmonary function (PF) test was performed by means of “SPIROKOM” device (Ukraine). The degree of overweight was determined by calculating the body mass index (BMI) using the formula І = m/h² (m – body mass in kilograms, h – height, in square meters (kg/m²). The level of leptin of systemic inflammatory markers was determined by a solid phase enzyme-linked immunosorbent assay in blood serum: “DRG Leptin Elisa” (Germany).
Results and conclusions: The study revealed that overweight leads to a more severe course of COPD (III degree of bronchial obstruction), and the determination of leptin may serve as a diagnostic criterion in the progression of this pathology.
References
Bychkova SA, Bychkova NH. Clinical and functional peculiarities of the course of chronic obstructive pulmonary disease combined with metabolic syndrome. Vrachebnoe Delo. 2014;7-8:54-59. DOI: https://doi.org/10.31450/ukrjnd.1(45).2015.02
Hashynova KYu. Influence of comorbid pathology on the frequency of hospitalizations with exacerbation on chronic obstructive pulmonary disease. Calician Medical Journal. 2014; 21(3):15-18.
Humeniuk MI, Ilyinska IF, Kharchenko-Sevriukova HS. Systemic inflammatory markers in patients with COPD. Ukr.Pulmonol.Zhurnal. 2014;3:33-36.
Dihtiar NI, Herasymenko ND, Savchenko LV, et al. Low-grade systemic inflammation as the common ground for chronic obstructive pulmonary disease and comorbid conditions. Ukr.Pulmonol.Zhurnal. 2016; 3: 64-68.64.
Konopkina LI. Diagnostic significance of some markers of systemic inflammation in the infectious exacerbation of chronic obstructive pulmonary disease. Ukr. Pulmonol. Zhurnal. 2012; 3: 31-34.
Mostovyy YuM. Chronic obstructive pulmonary disease. Key issues. Ukr.Med.Chasopys. 2016; 4: 63-66.
Order of the Ministry of Health of Ukraine №555 dated June 27, 2013 "On approval and implementation of medical-technological documents on standardization of medical care in chronic obstructive pulmonary disease". Kyiv, 2013:146p. URL: http://www.moz.gov.ua/ua/portal/dn_20131008_0868.html.
Ostrovskyy ММ, Mostovyy YuM, Pertseva TO. Obstructive pulmonary disease: the realities of clinical practice. Zdorovya Ukrayiny. 2017; 2: 5-7.
Ostrovskyy ММ, Stovban MP. Phenotype of COPD with frequent exacerbations: the influence on the rate of progression of the disease and the prognosis for the patient. Zdorovya Ukrayiny. 2013; 3(23): 29-30.
Pertseva TO, Sanina NA. The role of systemic inflammatory processes in the pathogenesis of chronic obstructive pulmonary disease. Ukr.Pulmonol.Zhurnal. 2012; 4: 48-50.
Mostovoi YuM, Rasputina LV, Dovhan AO, Ovcharuk MV. The problem of comorbid conditions in the National agreement on the diagnosis and treatment of chronic obstructive pulmonary disease from the standpoint of own experience. Discussion of the Order №555. Bukovynskyy Medychnyy Visnyk. 2014; 18(3): 221-226.
Savchenko LV, Kaydashev IP. The role of some proinflammatory cytokines in the development of chronic obstructive pulmonary disease against the background of obesity. Problemy ekolohiyi ta medytsyny.2015; 19(3/4): 7-9.
Savchenko LV, Kaidashev IP. Alimentary obesity as a result of eating behaviour violation impairs the clinical course of chronic obstructive pulmonary disease. Ukr. Pulmonol. Zhurnal. 2017; 2: 33-36.
Tolokh OS. Chronic obstructive pulmonary disease: new solutions to old problems. Klinichna imunolohiia. Alerholohiia. Infektolohiia. 2017; 1(98): 16-22.
Treumova SI, Petrov YeYe, Boriak VP. Chronic obstructive pulmonary disease combined with metabolic syndrome. Visnyk problem biolohii i medytsyny. 2015; 1: 33-36.
Feshchenko YuI. COPD in Ukraine: problems and ways of solution. Zdoroviyia Ukrayiny. March 27, 2015. http://health-ua.com/article/3876.html
Feshchenko YuI, Chaikovskyy YuB, Ostrovskyy MM, et al. Chronic obstructive pulmonary disease. New shades of the problem. Ivano-Frankivsk. 2016; 400.
Agusti A, Soriano JB. COPD as a systemic disease. COPD. 2008;5:133-138. DOI: https://doi.org/10.1080/15412550801941349 [PMid:18415812]
Rabe KF , Lichtinghagen R, et al. Angiopoietin-like protein 4 and cardiovascular function in COPD. BMJ Open Respiratory Research. 2016; 3, 1. DOI: https://doi.org/10.1136/bmjresp-2016-000161 [PMid:27933182 PMCid:PMC5133419]
Kumor-Kisielewska A, Kierszniewska-Stepien D, Pietras T, et al. Assessment of leptin and resistin in patients with chronic obstructive pulmonary disease. Polskie Archiwum Medycyny Wewnetrznei. 2013; 123(5):215-220. DOI: https://doi.org/10.20452/pamw.1724
Bhatt S. Adiponectin receptor: a potential target for diabetes, obesity and other disorders. Pharmacologyonline. 2010;1: 117-130.
Bing C, Mracek T, et al. Zinc-a2-glycoprotein: an adipokine modulator of body fat mass? International J. of Obesity. 2010; 34: 1559-1565. DOI: https://doi.org/10.1038/ijo.2010.105 [PMid:20514048]
Breyer M-K, Rutten EPA, Vernooy JHJ, et al. Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): A pivotal role of leptine. Respiratory Medicine. 2011; 105: 1046-1053. DOI: https://doi.org/10.1016/j.rmed.2011.02.001 [PMid:21367591]
Battaglia S, Spatafora M, Paglino G, et al. Ageing and COPD affect different domains of nutritional status: the ECCE study. Eur. Respir. J. 2011; 37: 1340-1345. DOI: https://doi.org/10.1183/09031936.00032310 [PMid:21071469]
Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Updated 2018. URL: http://www.goldcopd.com
Han MK, Agusti A, Calverley PM, et al. COPD phentypes: The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598-604. DOI: https://doi.org/10.1164/rccm.200912-1843CC [PMid:20522794 PMCid:PMC6850732]
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.